Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia

• Published in: Scientific reports Vol. 8; no. 1; pp. 11798 - 10
• Main Authors: Orsini, Paola, Minervini, Crescenzio F., Cumbo, Cosimo, Anelli, Luisa, Zagaria, Antonella, Minervini, Angela, Coccaro, Nicoletta, Tota, Giuseppina, Casieri, Paola, Impera, Luciana, Parciante, Elisa, Brunetti, Claudia, Giordano, Annamaria, Specchia, Giorgina, Albano, Francesco
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.08.2018; Nature Publishing Group
• Subjects: 45/23; 631/67/1990/283/1895; 631/67/69; Chronic lymphocytic leukemia; Data processing; Gene mapping; Genes; Humanities and Social Sciences; Leukemia; Lymphatic leukemia; multidisciplinary; MyD88 protein; p53 Protein; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-30330-y

We report a customized gene panel assay based on multiplex long-PCR followed by third generation sequencing on nanopore technology (MinION), designed to analyze five frequently mutated genes in chronic lymphocytic leukemia (CLL): TP53, NOTCH1, BIRC3, SF3B1 and MYD88. For this purpose, 12 patients were selected according to specific cytogenetic and molecular features significantly associated with their mutational status. In addition, simultaneous analysis of the targets genes was performed by molecular assays or Sanger Sequencing. Data analysis included mapping to the GRCh37 human reference genome, variant calling and annotation, and average sequencing depth/error rate analysis. The sequencing depth resulted on average higher for smaller amplicons, and the final breadth of coverage of the panel was 94.1%. The error rate was about 6% and 2% for insertions/deletions and single nucleotide variants, respectively. Our gene panel allows analysis of the prognostically relevant genes in CLL, with two PCRs per patient. This strategy offers an easy and affordable workflow, although further advances are required to improve the accuracy of the technology and its use in the clinical field. Nevertheless, the rapid and constant development of nanopore technology, in terms of chemistry advances, more accurate basecallers and analysis software, offers promise for a wide use of MinION in the future.